EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis

Adovich S Rivera iD, Jacob B Pierce, Arjun Sinha, Anna E Pawlowski iD, Donald M Lloyd-Jones, Yvonne C Lee, Matthew J Feinstein, Lucia C Petito

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Adovich S Rivera und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Public Health and Management, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Electronic Health Records, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Emulation of the “target trial” (TT), a hypothetical pragmatic randomized controlled trial (RCT), using observational data can be used to mitigate issues commonly encountered in comparative effectiveness research (CER) when randomized trials are not logistically, ethically, or financially feasible. However, cardiovascular (CV) health research has been slow to adopt TT emulation. Here, we demonstrate the design and analysis of a TT emulation using electronic health records to study the comparative effectiveness of the addition of a disease-modifying anti-rheumatic drug (DMARD) to a regimen of methotrexate on CV events among rheumatoid arthritis (RA) patients.

Methods

We used data from an electronic medical records-based cohort of RA patients from Northwestern Medicine to emulate the TT. Follow-up began 3 months after initial prescription of MTX (2000–2020) and included all available follow-up through June 30, 2020. Weighted pooled logistic regression was used to estimate differences in CVD risk and survival. Cloning was used to handle immortal time bias and weights to improve baseline and time-varying covariate imbalance.

Results

We identified 659 eligible people with RA with average follow-up of 46 months and 31 MACE events. The month 24 adjusted risk difference for MACE comparing initiation vs non-initiation of a DMARD was -1.47% (95% confidence interval [CI]: -4.74, 1.95%), and the marginal hazard ratio (HR) was 0.72 (95% CI: 0.71, 1.23). In analyses subject to immortal time bias, the HR was 0.62 (95% CI: 0.29–1.44).

Conclusion

In this sample, we did not observe evidence of differences in risk of MACE, a finding that is compatible with previously published meta-analyses of RCTs. Thoughtful application of the TT framework provides opportunities to conduct CER in observational data. Benchmarking results of observational analyses to previously published RCTs can lend credibility to interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsElectronic Health RecordsCardiovascular DiseasesMethotrexateHumansFemaleMaleMiddle AgedAgedTreatment OutcomeRandomized Controlled Trials as TopicComparative Effectiveness ResearchAdult

Substanzen

Antirheumatic AgentsMethotrexate

Autor:innen und Institutionen

  • Institute for Public Health and Management, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, United States of America.
  • Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.
  • Northwestern Medicine Enterprise Data Warehouse, Northwestern University, Chicago, Illinois, United States of America.
  • Department of Preventive Medicine, Division of Epidemiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America.

ORCID-Profile: Adovich S Rivera, Anna E Pawlowski

Zitieren

APA

Rivera, A. S., Pierce, J. B., Sinha, A., Pawlowski, A. E., Lloyd-Jones, D. M., Lee, Y. C., Feinstein, M. J., & Petito, L. C. (2024). Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis. PLOS ONE. https://doi.org/10.1371/journal.pone.0305467

Vancouver

Rivera AS, Pierce JB, Sinha A, Pawlowski AE, Lloyd-Jones DM, Lee YC, et al. Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis. PLOS ONE. 2024. doi:10.1371/journal.pone.0305467

BibTeX
@article{Rivera2024,
  author = {Rivera, Adovich S and Pierce, Jacob B and Sinha, Arjun and Pawlowski, Anna E and Lloyd-Jones, Donald M and Lee, Yvonne C and Feinstein, Matthew J and Petito, Lucia C},
  title = {Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305467}
}
Kostenlos starten →